Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Other Non-Current Assets (2019 - 2025)

Immunocore Holdings' Other Non-Current Assets history spans 4 years, with the latest figure at $20.3 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 18.49% year-over-year to $20.3 million; the TTM value through Dec 2025 reached $20.3 million, up 18.49%, while the annual FY2025 figure was $20.3 million, 18.49% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $20.3 million at Immunocore Holdings, up from $16.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $20.3 million in Q4 2025 and bottomed at $8.9 million in Q4 2022.
  • The 4-year median for Other Non-Current Assets is $16.8 million (2025), against an average of $16.1 million.
  • The largest annual shift saw Other Non-Current Assets skyrocketed 62.86% in 2023 before it dropped 4.35% in 2025.
  • A 4-year view of Other Non-Current Assets shows it stood at $8.9 million in 2022, then surged by 62.86% to $14.5 million in 2023, then rose by 18.27% to $17.1 million in 2024, then grew by 18.49% to $20.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Other Non-Current Assets are $20.3 million (Q4 2025), $16.5 million (Q3 2025), and $17.0 million (Q2 2025).